• Users Online:647
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2008  |  Volume : 2  |  Issue : 3  |  Page : 10-14

Ficus Religiosa: A multicentric double blind Homoeopathic Pathogenetic Trial (drug proving) carried out by CCRH*

1 Drug Proving Research Unit, Kolkata, West Bengal, India
2 Drug Proving Research Unit, Midnapore, West Bengal, India
3 Drug Proving Research Unit, Ghaziabad, Uttar Pradesh, India
4 Central Council for Research in Homoeopathy, New Delhi, India

Correspondence Address:
N R Dey
Central Council for Reaserch in Homoeopathy, 61-65, Institutional Area, Opp. D-Block, Janakpuri, New Delhi-110058
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Objective: Objective of the study was to elicit the pharmacodynamic response of the drug, Ficus religiosa on healthy human beings in non-toxic doses. Methodology: Drug was proved through a double-blind method and was a multi-centric study. Trial drug was proved in two potencies (30C and 200C) on 24 volunteers who were selected and declared apparently healthy during their pre-trial medical examination by specialists. The volunteers took 56 doses of each of the two potencies in three stages including one control stage for a varying period. The symptoms generated during the trial period were noted by the volunteers and elaborated and cross examined by the Proving Masters. The data obtained from different centers were compiled at proving-cum-data processing cell at CCRH headquarters after decoding the drug. Observation: Out of the 17 volunteers who were on actual drug trial, 11 manifested symptoms. Drug was able to produce symptoms in each potency more or less on every part of the body. Some of the symptoms have been reproved which are mentioned in the fragmentary provings published in different literatures. Conclusion: Symptoms appeared (new and reproved) during the proving trial will add to the literature available on the drug and benefit the research scholars and clinicians. This also needs verification through clinical application in different clinical conditions.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded331    
    Comments [Add]    

Recommend this journal